The ATTACH study reported that the use of anti-TNF therapy increased mortality or worsened heart failure in patients with moderate to severe chronic heart failure, especially those with an ischemic etiology, but the RENAISSANCE and RECOVER clinical trials did not confirm this for etanercept [120]. The gene discussed is TNF; the disease is congestive heart failure.